Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bioenvision Charts. Click Here for more Bioenvision Charts.](/p.php?pid=staticchart&s=N%5EBIVN&p=8&t=15)
Bioenvision, Inc. (NasdaqGM:BIVN) today announced MaryJane Rafii, Ph.D.
has joined the Company as Vice President, Regulatory Affairs effective
October 30th. Dr. Rafii brings to Bioenvision over 12 years of
pharmaceutical and biotechnology industry experience. The appointment
signals the Company’s focus on expanding the
markets for its approved products and developing the product pipeline.
Dr. Rafii was most recently the head of regulatory affairs at the Ludwig
Institute for Cancer Research in Manhattan where she had been since
1999. Dr. Rafii also oversaw regulatory affairs at Sankyo USA in New
York from 1995 to 1999. She began her regulatory career at Escalon
Ophthalmics in 1993.
“Dr. Rafii has the background to design
regulatory strategies appropriate for each of the products in our
pipeline and to manage certain of our clinical programs we have designed
or hope to design for our approved products. We are delighted to have
added MaryJane to our team,” said David P.
Luci, Chief Financial Officer and General Counsel of Bioenvision.
“Dr. Rafii’s
background in oncology will be instrumental in expanding the franchise
for our leukemia drug Evoltra® (clofarabine),”
said Dr. Christopher B. Wood, Chairman and Chief Executive Officer of
Bioenvision. “This drug has shown an
indication of activity for treating several types of cancer and on a
global basis could reach blockbuster status. Dr. Rafii will help the
Company maximize the potential for this innovative new therapy.”
MaryJane Rafii earned her Ph.D. in immunology and biochemistry from the
University of Cardiff, Wales, United Kingdom. She received her master’s
degree in protein modeling from UC San Francisco and a bachelor’s
degree in molecular biology/marketing and international finance from the
University of Southern California.
About Bioenvision
Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra®,
Modrenal® (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to initial
hormone therapy), and other products. Bioenvision is also developing
anti-infective technologies, including the OLIGON®
technology, an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus®,
an antimicrobial agent currently in clinical development for refractory
chronic hepatitis C infection. For more information on Bioenvision
please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking" statements
(as such term is defined in the Private Securities Litigation Reform Act
of 1995). Because these statements include risks and uncertainties,
actual results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to: risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's compounds
under development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for treatment of
disease; uncertainties inherent in the early stage of Bioenvision's
compounds under development; failure to successfully implement or
complete clinical trials; failure to receive marketing clearance from
regulatory agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that change
Bioenvision's business, structure or projections; the development of
competing products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in Bioenvision's
filings with the SEC. Bioenvision disclaims any obligation to update
these forward-looking statements.
Bioenvision, Inc. (NasdaqGM:BIVN) today announced MaryJane Rafii,
Ph.D. has joined the Company as Vice President, Regulatory Affairs
effective October 30th. Dr. Rafii brings to Bioenvision over 12 years
of pharmaceutical and biotechnology industry experience. The
appointment signals the Company's focus on expanding the markets for
its approved products and developing the product pipeline.
Dr. Rafii was most recently the head of regulatory affairs at the
Ludwig Institute for Cancer Research in Manhattan where she had been
since 1999. Dr. Rafii also oversaw regulatory affairs at Sankyo USA in
New York from 1995 to 1999. She began her regulatory career at Escalon
Ophthalmics in 1993.
"Dr. Rafii has the background to design regulatory strategies
appropriate for each of the products in our pipeline and to manage
certain of our clinical programs we have designed or hope to design
for our approved products. We are delighted to have added MaryJane to
our team," said David P. Luci, Chief Financial Officer and General
Counsel of Bioenvision.
"Dr. Rafii's background in oncology will be instrumental in
expanding the franchise for our leukemia drug Evoltra(R)
(clofarabine)," said Dr. Christopher B. Wood, Chairman and Chief
Executive Officer of Bioenvision. "This drug has shown an indication
of activity for treating several types of cancer and on a global basis
could reach blockbuster status. Dr. Rafii will help the Company
maximize the potential for this innovative new therapy."
MaryJane Rafii earned her Ph.D. in immunology and biochemistry
from the University of Cardiff, Wales, United Kingdom. She received
her master's degree in protein modeling from UC San Francisco and a
bachelor's degree in molecular biology/marketing and international
finance from the University of Southern California.
About Bioenvision
Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra(R), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies, including
the OLIGON(R) technology, an advanced biomaterial that has been
incorporated into various FDA approved medical devices and Suvus(R),
an antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.